Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score N/A
- Piotroski Score N/A
- Grade N/A
- Symbol (MYC)
- Company Blackrock MuniYield California Fund, Inc.
- Price $12.50
- Changes Percentage (-1.03%)
- Change -$0.13
- Day Low $12.49
- Day High $12.60
- Year High $13.84
Blackrock MuniYield California Fund, Inc. is a closed ended fixed income mutual fund launched BlackRock, Inc. It is managed by BlackRock Advisors, LLC. The fund invests in fixed income markets. It invests primarily in a portfolio of long-term investment grade municipal bonds that are exempt from federal and California income taxes. It also invests in short-term securities. Blackrock MuniYield California Fund, Inc. was formed on February 28, 1991 and is domiciled in United States.
- Last Earnings 03/24/2022
- Ex-Dividend for 5/16 Dividend 04/06/2022
- Dividend Payable 05/02/2022
- Today N/A
- Next Earnings (Estimated) N/A
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating N/A
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.94
- Trailing P/E Ratio 13.3
- Forward P/E Ratio 13.3
- P/E Growth 13.3
- Net Income $20.14 M
Income Statement
Quarterly
Annual
Latest News of MYC
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
What is rapamycin? Devotees claim the drug can slow down aging
Rapamycin, a compound used in organ transplant patients, is gaining attention as an anti-aging drug. By inhibiting mTOR, it may reduce inflammation, promote autophagy, and potentially combat diseases ...
By New York Post | 3 days ago -
Forbes EQ BrandVoice: DEI Consultant Dr. Jamyce Curtis Banks Does Whatever It Takes...And It's Never One-Size-Fits-All
Dr. Jamyce Curtis Banks transitioned from educator to DEI consultant, focusing on equity and inclusion in organizations. Through her consulting practice, she offers customized solutions to improve cul...
By Forbes | 3 weeks ago -
Formycon First Half 2024 Earnings: €0.58 loss per share (vs €0.11 profit in 1H 2023)
The chart displays figures for the trailing 12 months. Forecast predicts Formycon's revenue will increase by 33% annually for the next 3 years, outperforming the Biotechs industry in Europe at 20%. Th...
By Yahoo! Finance | 1 month ago